Comprehensive Review Updates Clinical Pharmacology of Kratom: Drug Interactions, Abuse Potential, and Future Directions

Why it matters

With an estimated 2–16 million annual kratom users in the U.S. and no federal regulatory framework, clinicians urgently need authoritative guidance on drug interactions, dosing risks, and when to be concerned. This multi-institution review from leading kratom researchers provides the most current clinical framework.

The big picture

Published by top kratom researchers from the University of Florida, Johns Hopkins, NIDA, and Midwestern University, this review compiles the state of knowledge on kratom's complex pharmacology. Kratom contains over 40 alkaloids interacting with opioid, serotonin, and adrenergic receptors simultaneously — making it pharmacologically distinct from classical opioids.

Key findings

• Mitragynine is metabolized primarily by CYP3A4, and even a low 2g kratom tea dose raised midazolam blood levels 1.4–1.5-fold, indicating real drug interaction risk
• Kratom alkaloids also inhibit CYP2D6, affecting metabolism of antidepressants, antipsychotics, and many other medications
• Kratom withdrawal symptoms are generally mild to moderate and shorter in duration than opioid withdrawal
• Kratom use disorder (KUD) appears primarily mild by DSM-5 criteria; regular high-dose use raises risk, especially for those with prior substance use disorders
• No randomized controlled trials for kratom in pain or opioid use disorder exist — evidence remains insufficient by AHRQ standards
• Concentrated extract products may carry substantially higher toxicity risk than traditional leaf preparations

What they say

The expert panel concluded: "Clinicians should be aware of the potential benefits and adverse effects associated with kratom. While many patients may benefit from kratom use with few or no reported adverse effects, escalating dose and increased use frequency raise the risk for toxic events in the setting of polysubstance use or development of a use disorder."

Bottom line

**This landmark multi-institution review confirms kratom has real drug interaction risks via CYP3A4 and CYP2D6 inhibition, mild-to-moderate dependence potential, and urgent need for clinical trials — while noting that concentrated extract products pose substantially higher risks than traditional leaf.**